RIP2 knockdown inhibits cartilage degradation and oxidative stress in IL-1β-treated chondrocytes via regulating TRAF3 and inhibiting p38 MAPK pathway

• Published in: Clinical immunology (Orlando, Fla.) Vol. 232; p. 108868
• Main Authors: Pan, DongSheng, Lyu, Yanhong, Zhang, Na, Wang, Xuankang, Lei, Tao, Liang, Zhuowen
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 01-11-2021
• Subjects: Osteoarthritis; p38; RIP2; TRAF3; p38; TRAF3; Osteoarthritis; RIP2
• ISSN: 1521-6616; 1521-7035
• DOI: 10.1016/j.clim.2021.108868

Receptor-interacting protein 2 (RIP2) is a key mediator implicated in multiple cellular processes, and its dysregulation has been recently reported in colitis, asthma and other inflammatory diseases. However, the effects of RIP2 on osteoarthritis (OA) and the underlying mechanisms remain unclear. In this study, we found that RIP2 expression was upregulated in human articular cartilage tissues with OA and interleukin-1β (IL-1β)-treated chondrocytes. Knockdown of RIP2 inhibited IL-1β-induced extracellular matrix (ECM) and oxidative stress. Moreover, knockdown of TRAF3 reversed the effects of RIP2 silencing on cartilage degradation and oxidative stress in IL-1β-induced chondrocytes. In addition, p38 mitogen-activated protein kinase (MAPK) activator dehydrocorydalmine chloride (Dc) also reversed the effects of RIP2 silencing on IL-1β-induced chondrocytes. Taken together, our data reveal that RIP2 knockdown inhibits cartilage degradation and oxidative stress in IL-1β-treated chondrocytes by regulating TRAF3 expression and p38 MAPK pathway activation.